價(jià)格 | 詢價(jià) |
包裝 | 10mM |
最小起訂量 | 10mM |
發(fā)貨地 | 上海 |
更新日期 | 2025-01-14 |
中文名稱:R1530 (VEGFR抑制劑) | 英文名稱:R1530 (VEGFR抑制劑) |
有效期: 一年 | 產(chǎn)品類別: 其它類別抑制劑激活劑 Angiogenesis |
產(chǎn)品編號(hào) | 產(chǎn)品名稱 | 產(chǎn)品包裝 | 產(chǎn)品價(jià)格 |
SF5404-10mM | R1530 (VEGFR抑制劑) | 10mM | 128.00元 |
化學(xué)信息:
化學(xué)名 | 5-(2-chlorophenyl)-7-fluoro-8-methoxy-3-methyl-1,2-dihydropyrazolo[3,4-b][1,4]benzodiazepine | |
簡(jiǎn)稱 | R1530 | |
別名 |
UNII-XQJ55R5PPQ, CHEMBL1980391, R1530, C18H14ClFN4O |
|
中文名 | N/A | |
化學(xué)式 | C18H14ClFN4O | |
分子量 | 356.78 | |
CAS號(hào) | 882531-87-5 | |
純度 | 98% | |
溶劑/溶解度 |
Water<1mg/ml; DMSO54mg/ml; Ethanol<1mg/ml |
|
溶液配制 | 5mg加入1.4ml DMSO,或者每3.57mg加入1ml DMSO,配制成10mM溶液。SF5404-10mM用DMSO配制。 |
生物信息:
產(chǎn)品描述 | R1530 is the multikinase inhibitor with potential antiangiogenesis and antineoplastic activities. R1530 is also a mitosis-angiogenesis inhibitor (MAI) that inhibits multiple receptor tyrosine kinases involved in angiogenesis, such as vascular endothelial growth factor receptor (VEGFR)-1, -2, -3, platelet-derived growth factor receptor (PDGFR) beta FMS-like tyrosine kinase (Flt)-3, and fibroblast growth factor receptor (FGFR) -1, -2. In addition, this agents exhibits anti-proliferative activity by initiating mitotic arrest and inducing apoptosis. | ||||
信號(hào)通路 | Protein Tyrosine Kinase | ||||
靶點(diǎn) | VEGFR | PDGFR | - | - | - |
IC50 | - | - | - | - | - |
體外研究 | In the presence of R1530, polyploid cancer cells underwent apoptosis or became senescent which translated into potent in vitro and in vivo efficacy. Normal proliferating cells were resistant to R1530-induced polyploidy thus supporting the rationale for cancer therapy by induced polyploidy. Mitotic checkpoint kinase BubR1 was found downregulated during R1530-induced exit from mitosis, a likely consequence of PLK4 inhibition. R1530 strongly inhibited human tumor cell proliferation. Growth factor-driven proliferation of endothelial and fibroblast cells was also inhibited. | ||||
體內(nèi)研究 | Significant tumor growth inhibition was demonstrated in a lung cancer xenograft model with a range of once daily, weekly and twice-weekly doses of R1530 (3.125-50mg/kg qd, 100mg/kg qw, 100mg/kg biw). Daily doses were most effective in the lung cancer model and also had significant growth inhibitory effects in models of colorectal, prostate, and breast tumors. Tumor regression occurred in all models treated with the maximum tolerated daily dose (50mg/kg). The doses of 25 and 50mg/kg qd resulted in biologically significant increased survival in all tested models. After oral administration in nude mice, R1530 showed good tissue penetration. Exposure was dose dependent up to 100mg/kg with oral administration. | ||||
臨床實(shí)驗(yàn) | A Multiple Ascending Dose Study of R-1530 in Patients With Advanced Solid Tumors. Phase 1. | ||||
特征 | N/A |
相關(guān)實(shí)驗(yàn)數(shù)據(jù)(此數(shù)據(jù)來(lái)自于公開(kāi)文獻(xiàn),碧云天并不保證其有效性):
酶活性檢測(cè)實(shí)驗(yàn) | |
方法 | N/A |
細(xì)胞實(shí)驗(yàn) | |
細(xì)胞系 | N/A |
濃度 | N/A |
處理時(shí)間 | N/A |
方法 | N/A |
動(dòng)物實(shí)驗(yàn) | |
動(dòng)物模型 | N/A |
配制 | N/A |
劑量 | N/A |
給藥方式 | N/A |
產(chǎn)品編號(hào) | 產(chǎn)品名稱 | 包裝 |
SF5404-10mM | R1530 (VEGFR抑制劑) | 10mM×0.2ml |
SF5404-5mg | R1530 (VEGFR抑制劑) | 5mg |
SF5404-25mg | R1530 (VEGFR抑制劑) | 25mg |
— | 說(shuō)明書 | 1份 |
保存條件:
????????-20℃保存,至少一年有效。5mg和25mg包裝也可室溫保存,至少6個(gè)月有效。如果溶于非DMSO溶劑,建議分裝后-80℃保存,預(yù)計(jì)6個(gè)月內(nèi)有效。
成立日期 | 2007-07-19 (18年) | 注冊(cè)資本 | 1000.000000萬(wàn)人民幣 |
員工人數(shù) | 500人以上 | 年?duì)I業(yè)額 | ¥ 500萬(wàn)-1000萬(wàn) |
主營(yíng)行業(yè) | 生化試劑,核苷,核苷酸,寡核苷酸,抗體,蛋白組學(xué),生物活性小分子 | 經(jīng)營(yíng)模式 | 試劑 |
產(chǎn)品名稱 | 價(jià)格 | 公司名稱 | 報(bào)價(jià)日期 | |
---|---|---|---|---|
詢價(jià) |
VIP3年
|
武漢佰樂(lè)博生物技術(shù)有限公司
|
2025-01-17 | |
¥1650 |
VIP6年
|
上??道噬锟萍加邢薰?/div>
|
2025-01-17 | |
詢價(jià) |
VIP6年
|
上海澤葉生物科技有限公司
|
2025-01-17 |